Literature DB >> 10223353

Reduced intimal thickening following alpha(v)beta3 blockade is associated with smooth muscle cell apoptosis.

R van der Zee1, T Murohara, J Passeri, M Kearney, D A Cheresh, J M Isner.   

Abstract

The adhesion integrin alpha(v)beta3 is expressed by both activated endothelial cells (ECs) and smooth muscle cells (SMCs). Peptide and antibody antagonists of alpha(v)beta3 have been shown to block angiogenesis by initiating unscheduled programmed cell death of proliferating ECs. The present study was designed to determine if antagonism of alpha(v)beta3 immediately following balloon injury might similarly lead to programmed cell death among activated SMCs, and thereby inhibit intimal thickening. LM609, a monoclonal antibody antagonist of alpha(v)beta3, was administered locally and/or systemically immediately after balloon angioplasty in a rabbit model of vascular injury. Immunohistochemical studies documented that LM609, even when administered systemically, localized to sites of vascular injury. LM609 administered immediately following balloon injury of the external iliac artery markedly reduced intimal thickening at 2 and 4 wk post-injury. Apoptosis was abundant where balloon injury resulted in expression of alpha(v)beta3. At both 2 and 4 wk, re-endothelialization at the site of balloon injury was not retarded in LM609-treated rabbits versus controls. Thus, blockade of alpha(v)beta3 inhibits intimal thickening when administered immediately following balloon injury. This favorable impact on neointimal thickening is associated with apoptosis of activated SMCs expressing alpha(v)beta3. These findings may explain the reduction in restenosis observed clinically following beta3 integrin blockade.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10223353     DOI: 10.3109/15419069809109146

Source DB:  PubMed          Journal:  Cell Adhes Commun        ISSN: 1023-7046


  7 in total

1.  Regulation of smooth muscle cell migration and integrin expression by the Gax transcription factor.

Authors:  B Witzenbichler; Y Kureishi; Z Luo; A Le Roux; D Branellec; K Walsh
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 2.  Integrin signaling in atherosclerosis.

Authors:  Alexandra C Finney; Karen Y Stokes; Christopher B Pattillo; A Wayne Orr
Journal:  Cell Mol Life Sci       Date:  2017-02-28       Impact factor: 9.261

3.  Alteration of pulmonary artery integrin levels in chronic hypoxia and monocrotaline-induced pulmonary hypertension.

Authors:  Anita Umesh; Omkar Paudel; Yuan-Ning Cao; Allen C Myers; James S K Sham
Journal:  J Vasc Res       Date:  2011-08-10       Impact factor: 1.934

Review 4.  Integrin alpha(v)beta(3) as a target in the prevention of neointimal hyperplasia.

Authors:  Taku Kokubo; Hisashi Uchida; Eric T Choi
Journal:  J Vasc Surg       Date:  2007-06       Impact factor: 4.268

Review 5.  Antiangiogenesis -- therapeutic strategies and clinical implications for brain tumors.

Authors:  V K Puduvalli; R Sawaya
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.506

6.  Effects of abciximab on key pattern of human coronary restenosis in vitro: impact of the SI/MPL-ratio.

Authors:  Rainer Voisard; Mustafa Alan; Lutz von Müller; Regine Baur; Vinzenz Hombach
Journal:  BMC Cardiovasc Disord       Date:  2006-04-04       Impact factor: 2.298

Review 7.  Role of Integrins in Modulating Smooth Muscle Cell Plasticity and Vascular Remodeling: From Expression to Therapeutic Implications.

Authors:  Manish Jain; Anil K Chauhan
Journal:  Cells       Date:  2022-02-13       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.